Health Care
Cynata Therapeutics Limited (CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian biotechnology company focused on developing innovative cellular therapies for serious diseases using its proprietary Cell Control Technology. Operating primarily in the Australian market with research collaborations globally, its key product in development is rCTRM, a mesenchymal stromal cell therapy for acute respiratory distress syndrome (ARDS) and other inflammatory conditions.
Market Cap
A$83M
Shares on Issue
N/A
Price Chart
AI Analysis
Cynata Therapeutics is at a pivotal stage, having transitioned from preclinical to clinical phases with its flagship product, rCTRM. Recent performance has been driven by milestones in clinical trial enrollments and partnerships, though as a small-cap biotech, it remains speculative with a market cap of A$83M. Key metrics include successful trial outcomes and strategic partnerships.
The company's growth outlook hinges on successful clinical trial results, particularly for ARDS, and securing additional partnerships or funding. Strategic direction is centered around expanding the therapeutic indications for rCTRM and potentially licensing its technology to larger pharmaceutical players.
Bull Case
- • Successful Phase II/III clinical trial results for rCTRM in ARDS could lead to accelerated approval and significant revenue potential.
- • Strategic partnership or licensing agreement with a major pharmaceutical company, providing financial backing and development expertise.
- • Expansion of rCTRM into additional high-need inflammatory conditions, diversifying the revenue stream.
Bear Case
- • Unfavorable clinical trial outcomes for rCTRM, potentially halting development and significantly impacting valuation.
- • Failure to secure necessary funding, either through partnerships or capital raises, to support clinical development.
- • Increased competition from established biotech firms or novel therapies targeting similar indications.
Recent Announcements
Cynata to Present at 2026 Euroz Hartleys Healthcare Forum
Investor Webinar
December 2025 Quarterly Activity Report and Appendix 4C
🚨 Price SensitiveThe ASX Commitments Test Entity for CYP has released its quarterly report, detailing significant financial activities expected to conclude by the end of Q3 in December 2025.
Cynata Completes $1.2m At-The-Market Raise
🚨 Price SensitiveCynata Corporation has successfully raised $1.2 million through an at-the-market offering on the ASX, providing additional capital for its operations and growth initiatives; investors are invited to participate in this opportunity by purchasing shares directly from CYP's open market program
FAQs
What does CYP do?
Cynata develops innovative cellular therapies, notably rCTRM for ARDS and other inflammatory conditions, using its Cell Control Technology.
Is CYP a good investment?
CYP offers high-risk, high-reward potential typical of small-cap biotechs. Success in clinical trials and strategic partnerships could drive growth, but development risks and funding uncertainties are significant.
What drives CYP's share price?
Key drivers include clinical trial outcomes, partnership announcements, funding success, and broader biotech sector trends, given its speculative and small-cap nature.
Key Metrics
Related Stocks
Health Care
CSLCSL Ltd
A$181.24
-27.3% 1Y
CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics.
Health Care
PNVPolynovo Ltd
A$0.99
-13.1% 1Y
Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery.
Health Care
1ADAdalta Limited
A$0.01
-25.6% 1Y
Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases.